HRP20241477T1 - Postupci liječenja mijeloproliferativne neoplazme povezane s mijelofibrozom i anemijom - Google Patents

Postupci liječenja mijeloproliferativne neoplazme povezane s mijelofibrozom i anemijom Download PDF

Info

Publication number
HRP20241477T1
HRP20241477T1 HRP20241477TT HRP20241477T HRP20241477T1 HR P20241477 T1 HRP20241477 T1 HR P20241477T1 HR P20241477T T HRP20241477T T HR P20241477TT HR P20241477 T HRP20241477 T HR P20241477T HR P20241477 T1 HRP20241477 T1 HR P20241477T1
Authority
HR
Croatia
Prior art keywords
signaling inhibitor
actriib signaling
subject
use according
amino acid
Prior art date
Application number
HRP20241477TT
Other languages
English (en)
Croatian (hr)
Inventor
Abderrahmane LAADEM
Robert Gale
Original Assignee
Celgene Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64660712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20241477(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corporation filed Critical Celgene Corporation
Publication of HRP20241477T1 publication Critical patent/HRP20241477T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HRP20241477TT 2017-06-14 2018-06-13 Postupci liječenja mijeloproliferativne neoplazme povezane s mijelofibrozom i anemijom HRP20241477T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762519725P 2017-06-14 2017-06-14
US201862679210P 2018-06-01 2018-06-01
PCT/US2018/037213 WO2018231905A1 (en) 2017-06-14 2018-06-13 Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia
EP18816685.4A EP3638243B1 (en) 2017-06-14 2018-06-13 Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia

Publications (1)

Publication Number Publication Date
HRP20241477T1 true HRP20241477T1 (hr) 2025-01-03

Family

ID=64660712

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20241477TT HRP20241477T1 (hr) 2017-06-14 2018-06-13 Postupci liječenja mijeloproliferativne neoplazme povezane s mijelofibrozom i anemijom

Country Status (16)

Country Link
US (1) US20200101134A1 (cg-RX-API-DMAC7.html)
EP (2) EP4454707A3 (cg-RX-API-DMAC7.html)
JP (2) JP7496686B2 (cg-RX-API-DMAC7.html)
CN (1) CN111050770A (cg-RX-API-DMAC7.html)
DK (1) DK3638243T3 (cg-RX-API-DMAC7.html)
ES (1) ES2991738T3 (cg-RX-API-DMAC7.html)
FI (1) FI3638243T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241477T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068733T2 (cg-RX-API-DMAC7.html)
LT (1) LT3638243T (cg-RX-API-DMAC7.html)
PL (1) PL3638243T3 (cg-RX-API-DMAC7.html)
PT (1) PT3638243T (cg-RX-API-DMAC7.html)
RS (1) RS66093B1 (cg-RX-API-DMAC7.html)
SI (1) SI3638243T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400437T1 (cg-RX-API-DMAC7.html)
WO (1) WO2018231905A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
EP3227675B1 (en) 2014-12-03 2023-03-15 Celgene Corporation Activin-actrii antagonists and uses for treating myelodysplastic syndrome
EP3298034A4 (en) 2015-05-20 2019-02-13 Celgene Corporation IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS
LT3490582T (lt) 2016-07-27 2024-07-25 Acceleron Pharma Inc. Kompozicijos, skirtos naudoti gydant mielofibrozę
CA3043184A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
IL278546B2 (en) 2018-05-09 2026-03-01 Keros Therapeutics Inc Activin receptor type IIA variants and methods of using them
JP7663502B2 (ja) * 2018-10-31 2025-04-16 セルジーン コーポレイション 環状鉄芽球が見られる対象における非常に低リスク、低リスクまたは中程度のリスクの骨髄異形成症候群による貧血の、アクチビン-actriiリガンドトラップを用いた治療
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
EP4121078A4 (en) 2020-03-20 2024-08-14 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF
US20230181690A1 (en) * 2020-04-13 2023-06-15 Celgene Corporation Methods for treating anemia using an actriib ligand trap and fedratinib
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
CA3177632A1 (en) * 2020-05-15 2021-11-18 Melih ACAR Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
WO2022271716A2 (en) * 2021-06-21 2022-12-29 Keros Therapeutics, Inc. Methods of using activin receptor type ii signaling inhibitors
EP4387737A4 (en) * 2021-08-19 2025-06-18 Keros Therapeutics, Inc. METHODS OF USING INHIBITORS OF ACTIVIN RECEPTOR TYPE II SIGNALING
WO2025137373A1 (en) * 2023-12-19 2025-06-26 Cellarity, Inc. Disease detection systems and methods

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
EP0830459B1 (en) 1995-04-11 2007-01-24 The General Hospital Corporation Reverse two-hybrid systems
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ActRII受容体ポリペプチド、方法、および組成物
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
DK3750552T5 (da) 2008-08-14 2024-08-26 Acceleron Pharma Inc Gdf-fælder
KR102170682B1 (ko) 2009-08-13 2020-10-28 악셀레론 파마 인코포레이티드 적혈구 수준을 증가시키기 위한 gdf 트랩과 에리트로포이에틴 수용체 활성인자의 병용
DK3520805T3 (da) 2011-10-17 2021-04-19 Acceleron Pharma Inc Sammensætninger til behandling af myelofibrose
JP2017509647A (ja) 2014-03-21 2017-04-06 アクセルロン ファーマ, インコーポレイテッド アクチビンbおよび/またはgdf11の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
EP3227675B1 (en) 2014-12-03 2023-03-15 Celgene Corporation Activin-actrii antagonists and uses for treating myelodysplastic syndrome
TWI814187B (zh) * 2015-05-13 2023-09-01 美商西建公司 使用ACTRII配位體捕捉以治療β-地中海型貧血
WO2017024171A1 (en) * 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
JP7072507B2 (ja) * 2015-11-23 2022-05-20 アクセルロン ファーマ インコーポレイテッド 眼の障害を処置するための方法
LT3490582T (lt) * 2016-07-27 2024-07-25 Acceleron Pharma Inc. Kompozicijos, skirtos naudoti gydant mielofibrozę

Also Published As

Publication number Publication date
EP4454707A3 (en) 2024-12-25
PL3638243T3 (pl) 2025-02-10
WO2018231905A1 (en) 2018-12-20
CN111050770A (zh) 2020-04-21
EP3638243A4 (en) 2021-03-17
DK3638243T3 (da) 2024-10-28
EP4454707A2 (en) 2024-10-30
US20200101134A1 (en) 2020-04-02
JP2024075579A (ja) 2024-06-04
RS66093B1 (sr) 2024-11-29
PT3638243T (pt) 2024-10-31
JP7496686B2 (ja) 2024-06-07
LT3638243T (lt) 2024-11-11
ES2991738T3 (es) 2024-12-04
WO2018231905A8 (en) 2020-01-30
SI3638243T1 (sl) 2025-03-31
EP3638243B1 (en) 2024-08-07
HUE068733T2 (hu) 2025-01-28
SMT202400437T1 (it) 2024-11-15
FI3638243T3 (fi) 2024-10-29
EP3638243A1 (en) 2020-04-22
JP2020524139A (ja) 2020-08-13

Similar Documents

Publication Publication Date Title
FI3638243T3 (fi) Menetelmiä myeloproliferatiivin neoplasma-assosioidun myelofibroosin ja anemian hoitamiseksi
Kontzias et al. The use of Canakinumab, a novel IL-1β long-acting inhibitor, in refractory adult-onset Still's disease
Nobile‐Orazio Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go
JP2020524139A5 (cg-RX-API-DMAC7.html)
CA2934911C (en) Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury
RU2019106804A (ru) Лечение и устойчивая вирусологическая ремиссия при вич-инфекции у haart-стабилизированных пациентов с помощью антител против cd4
Cantarini et al. Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future
JP2018520094A5 (cg-RX-API-DMAC7.html)
Distler et al. RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis
JP5646617B2 (ja) 多発性硬化症の治療のための組成物および方法
HRP20161221T1 (hr) Tr1 stanice za liječenje artritičnih stanja
RU2015116264A (ru) Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
Sakallioglu et al. Etanercept in the treatment of arthritis in a patient with familial Mediterranean fever
Sutherland et al. A study of the major australian snake venoms in the monkey (Macaca fascicularis): I. the movement of injected venom, methods which retard this movement, and the response to antivenoms
Stohl et al. B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks?
EP4401743B1 (en) Composition comprising sodium hyaluronate and amino acids for use in the orthopedic field
KR20140031892A (ko) 항체 및/또는 인슐린 유사 성장 인자 길항제로 이루어진 약물의 용도
RU2017112967A (ru) Лечение и функциональное излучение вич-инфекции моноклональными антителами к cd4, опосредующими конкуретное ингибирование входа вич
RU2020117362A (ru) Способы лечения тендинопатии с помощью антагонистов интерлейкина-17 (il-17)
KR20170066344A (ko) 약제로서의 캡시노이드 및 그의 용도
JP2023523568A5 (cg-RX-API-DMAC7.html)
RU2261105C1 (ru) Способ профилактики клещевого энцефалита
Wimer et al. Mitogen information summaries
RU2473364C2 (ru) Способ лечения клещевого энцефалита
Majdan et al. Etanercept in a therapeutic program for the treatment of rheumatoid arthritis and ankylosing spondylitis–7 years’ personal experience